Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker

Genetics in Medicine

Volumn 11, Issue 7, 2009, Pages 536-541

  Young, Sarah P ^a,c   Zhang, Haoyue ^a   Corzo, Deyanira ^b   Thurberg, Beth L ^b   Bali, Deeksha ^a   Kishnani, Priya S ^a   Millington, David S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GENZYME CORPORATION   (United States)

^c Biochemical Genetics Laboratory   (United States)

Author keywords

Biomarker; Enzyme replacement therapy; Glucose tetrasaccharide; Pompe disease; Tandem mass spectrometry

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CREATINE KINASE; GLUCOSE TETRASACCHARIDE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; TETRASACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; ENZYME REPLACEMENT; GLUCOSE URINE LEVEL; GLYCOGEN MUSCLE LEVEL; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; INFANT; LABORATORY TEST; LONG TERM CARE; MORPHOMETRICS; MOTOR PERFORMANCE; MUSCLE INJURY; ONSET AGE; PATIENT MONITORING; SKELETAL MUSCLE; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

ALANINE TRANSAMINASE; ALPHA-GLUCOSIDASES; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CREATINE KINASE; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; INFANT, NEWBORN; MONITORING, PHYSIOLOGIC; MUSCLE, SKELETAL; OLIGOSACCHARIDES; TANDEM MASS SPECTROMETRY;

EID: 68749119738     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181a87867     Document Type: Article

References (18)

1. Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York, NY: McGraw-Hill, 2001:3389-3420.
2. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
3. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006;149:89-97.
4. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109.
5. Erratum in Neurology 2008;71:1748.
6. Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT. Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24:266-274.
7. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Pediatrics 2004;113:e448-e457.
8. Kling L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31.
9. Rossi M, Parenti G, Della Casa R, et al. Long-term enzyme replacement therapy for Pompe disease with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells. J Child Neurol 2007;22:565-573.
10. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of preand post-treatment pathology after enzyme replacement for Pompe disease. Lab Invest 2006;86:1208-1220.
11. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-288.
12. Ugorski M, Seder A, Lundblad A, Zopf D. Studies on the metabolic origin of a glucose-containing tetrasaccharide in human urine. J Exp Pathol 1983;1:27-38.
13. Kumlien J, Chester MA, Lindberg BS, Pizzo P, Zopf D, Lundblad A. Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen. Clin Chim Acta 1988;176:39-48.
14. An Y, Young SP, Kishnani PS, et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 2005;85:247-254.
15. Young SP, Stevens RD, An Y, Chen YT, Millington DS. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray tandem mass spectrometry. Anal Biochem 2003;316:175-180.
16. McVie-Wylie AJ, Lee KL, Qiu H, et al. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab 2008;94:448-455.
17. Lynch CM, Johnson J, Vaccaro C, Thurberg BL. High resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J Histochem Cytochem 2005;53:63-73.
18. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe disease. N Engl J Med 2009;360:194-195.